The life sciences industry is experiencing a digital transformation. Patients’ expectations have grown with the amount of health-related information available online, and almost 67% of healthcare professionals are set to become digital natives by 2020. Digital footprints are left at every stage of their journey and the Pharma industry must use all available insights to ensure relevant and contextual engagement.
The pharmaceutical marketing landscape has changed significantly due to the emergence of several types of “health systems” (e.g., ACOs, IDNs, IHNs, etc.), and the multiple physicians, clinics, and hospitals affiliated to these organizations. Most companies have well-established methodologies to calculate the potential of individual accounts but, since there are potential overlaps within different accounts, it is difficult to measure the potential at a health system level. It is this point that prompted the thought for this topic.
In addition to Axtria’s presentations and posters (discussed in our first blog on Axtria’s participation in PMSA’s 2018 Annual Conference), Axtria’s Principal, Devesh Verma, Ph.D., will be moderating a Next Generation Analytics Panel Discussion with roundtable participation. This session will take place on Tuesday, May 1, at 3:30 p.m.
In our previous PMSA blogs we talked about Axtria’s presentations in the General Sessions. In this blog, we will dive into the informative PMSA poster presentations. Axtria will be presenting 2 of the 16 posters being showcased in the poster session.
As part of Axtria’s exciting presentation lineup, David Wood, Senior Principal, and Shubham Lahoti, Associate Director, will be presenting on the topic of “Measuring Direct and Indirect Influence of Account Managers”.
As a follow-up to our first Pharmaceutical Management Science Association (PMSA) blog on Axtria’s participation in PMSA’s 2018 Annual Conference, we would now like to draw your attention to the thought-leading presentation we have planned for April 30th.
We are excited to announce that Axtria will be participating in the Pharmaceutical Management Science Association’s (PMSA) annual conference yet again. This year’s theme is “Next Generation Analytics.”
When new drugs enter the market, there are often delays before patients have access to the medication. These delays are partly due to patients and physicians being required to complete several steps before a prescription is approved for reimbursement. Alirocumab, a PCSK9 inhibitor which reduces low-density lipoprotein cholesterol (LDL-C)1, has up to a 75% rejection rate by payers2. The natural question that follows is what impact this delay may have on a patient’s health.
We are excited to announce Axtria’s participation at eyeforpharma Barcelona 2018. The conference takes place March 13th -15th and is one of Europe's most influential conferences in pharma, with more than 1300 attendees expected. This is the first time Axtria is part of this mega-event, and we look forward to engaging discussions across all aspects of commercial planning and operations.
Estimating the size of a target patient population is critical for many stakeholders within the healthcare industry. For pharmaceutical companies, a strong understanding of the patient population should feed into research & development, forecasting, physician targeting, and discussions with payers and health technology authorities (HTAs). For payers, the size of the target patient population aids in estimating the budget impact of treatments and the overall burden of disease.